{"schema_version":"secwatch.filing_event.v1","accession":"0001650664-24-000120","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2024-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.109005+00:00","generated_at":"2026-05-30T06:08:13.972618+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Editas Q3 net loss widens to $62.1M; cash runway extended into Q2 2026","bullets":["Q3 2024 net loss of $62.1M ($0.75/sh) vs $45.0M ($0.55/sh) in Q3 2023; R&D spend up $7.1M.","Cash, equivalents and securities $265.1M at Sept 30; with DRI $57M upfront totals ~$322.1M.","In vivo preclinical proof of concept for HBG1/2 editing in HSPCs using targeted LNP achieved.","Reni-cel partnering process with Moelis & Co underway; 28-patient RUBY update at ASH in December.","Collaboration revenue fell to $0.1M from $5.3M on prior-year Vor Bio upfront payment."],"urls":{"canonical":"https://secwatch.observer/filing/0001650664-24-000120","json":"https://secwatch.observer/filing/0001650664-24-000120.json","markdown":"https://secwatch.observer/filing/0001650664-24-000120.md","text":"https://secwatch.observer/filing/0001650664-24-000120.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000120/0001650664-24-000120-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000120/edit-20241104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T06:08:13.972618+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}